Ieq Capital LLC Purchases 507 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ieq Capital LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,531 shares of the biopharmaceutical company’s stock after purchasing an additional 507 shares during the period. Ieq Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $5,814,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in REGN. Brighton Jones LLC grew its holdings in Regeneron Pharmaceuticals by 1.5% in the second quarter. Brighton Jones LLC now owns 920 shares of the biopharmaceutical company’s stock worth $967,000 after purchasing an additional 14 shares during the period. Intech Investment Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 17.4% during the second quarter. Intech Investment Management LLC now owns 15,143 shares of the biopharmaceutical company’s stock valued at $15,916,000 after purchasing an additional 2,245 shares during the last quarter. Mark Sheptoff Financial Planning LLC boosted its position in shares of Regeneron Pharmaceuticals by 35.0% in the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 135 shares of the biopharmaceutical company’s stock worth $142,000 after purchasing an additional 35 shares in the last quarter. MRP Capital Investments LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $306,000. Finally, Vanguard Personalized Indexing Management LLC increased its position in Regeneron Pharmaceuticals by 13.4% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 9,559 shares of the biopharmaceutical company’s stock valued at $10,047,000 after buying an additional 1,129 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.4 %

Regeneron Pharmaceuticals stock opened at $1,145.03 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,211.20. The stock has a fifty day moving average of $1,131.75 and a 200 day moving average of $1,031.74. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The stock has a market cap of $126.17 billion, a PE ratio of 33.83, a price-to-earnings-growth ratio of 3.93 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same quarter in the prior year, the firm earned $8.79 EPS. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Barclays boosted their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. TD Cowen upped their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, September 16th. Piper Sandler upped their target price on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research note on Friday, August 23rd. Finally, Truist Financial reissued a “buy” rating and set a $1,200.00 price target (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,111.30.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,467,684. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the sale, the director now owns 1,382 shares in the company, valued at $1,467,684. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,026 shares of company stock valued at $11,498,705. Insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.